High price for Fuzeon
Roche is making HIV agent Fuzeon (T-20) available in Europe under a pre-license sales program for a price of approximately $50 per day. If that price is a benchmark for the U.S. launch price, it would significantly exceed the cost of other HIV therapies. Roche says the premium price is necessary because "Fuzeon is one of the most complex and challenging molecules ever chemically manufactured by the pharmaceutical industry at large scale, requiring 45 kg of raw materials for 1 kg of Fuzeon, and more than 100 production steps"...
You may also be interested in...
AIDS Drug Assistance Program coverage of Roche's antiretroviral Fuzeon could hinge upon the agent's role as either replacement or add-on therapy
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.